These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 8694537)

  • 41. [Evaluation of tumor markers in the management of small cell lung cancer].
    Ariyoshi Y
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma].
    Lorenz J; Gillmann-Blum D; Jensen M; Kreienberg R
    Pneumologie; 1990 Nov; 44(11):1259-63. PubMed ID: 2177891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
    Brockmann JG; St Nottberg H; Glodny B; Sprakel B; Senninger N
    Anticancer Res; 2000; 20(6D):4899-904. PubMed ID: 11332443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biological markers in lung cancer: A clinician's perspective.
    Tufman A; Huber RM
    Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.
    Viñolas N; Molina R; Galán MC; Casas F; Callejas MA; Filella X; Grau JJ; Ballesta AM; Estape J
    Anticancer Res; 1998; 18(1B):631-4. PubMed ID: 9584045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
    Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
    Lung; 2001; 179(1):57-65. PubMed ID: 11479694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [CYFRA 21-1: initial experiences in bronchus carcinoma and other tumors].
    Hoefliger M; Morant R; Riesen W; Baumgartner G; Engler H
    Schweiz Med Wochenschr; 1994 Nov; 124(44):1966-70. PubMed ID: 7973529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
    Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
    Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
    Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
    Mroczko B; Szmitkowski M; Czygier M
    Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cut-off levels of NSE to differentiate SCLC from NSCLC.
    Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
    Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
    Berzinec P; Zuffová H; Letkovicová M; Arpásová M
    Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
    Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
    Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
    Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
    Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
    Yang J; Li R; Li A
    Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
    Lin WY; Yen TC; Cheng KY; Wang SJ
    Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.